Jessica Lucero, NP
Payments from drug & device makers
Across 38 payments — averaging $62.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kerecis Limited$2K
- Organogenesis Inc.$140
- Smith+Nephew$104
- Lilly USA, LLC$95
- Merck$54
- Takeda Pharmaceuticals U.S.A., Inc.$52
- plus $268 from 13 others
What the payments were for
- Travel & lodging$1,40559%
- Food & beverage$96841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kerecis Limited | 4 | $1,658 |
| Organogenesis Inc. | 4 | $140 |
| Smith+Nephew | 5 | $104 |
| Lilly USA, LLC | 6 | $95 |
| Merck | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| Solventum Corporation | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Cashflow Solutions, LLC | 1 | $26 |
| Stryker | 1 | $24 |
| Reapplix Inc. | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Gilead | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| KCI USA, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Hartmann USA, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis Omega3 Marigen$6,342
- Kerecis Omega3 SurgiClose$1,586
How this compares
$2,373 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tobramycin Sulfate | 13 | $24,719 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $111 |
Paid to pharmacies, not to this prescriber.
Other family in Boone
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.